Hospira, now a wholly owned subsidiary of Pfizer
Hospira, now a wholly owned subsidiary of Pfizer sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 8 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Ventricular Repolarization, with 1 trials.
Trial Pipeline
15 total, page 1 of 1
Open-Label, Safety Study Evaluating the Use of Dexmedetomidine in Pediatric Subjects Undergoing Procedure-Type Sedation
NCT01519167
Open-Label, Safety, and Efficacy Study of Dexmedetomidine in Preterm Subjects Ages ≥28 Weeks to <36 Weeks Gestational Age
NCT01508455
Phase II Pharmacokinetic and Pharmacodynamic Study of DEX in Subjects Aged 12 Months Through <24 Months
NCT01378988
Safety, Efficacy and Pharmacokinetic Study of Dexmedetomidine in Pediatrics Ages ≥28 Weeks to ≤44 Weeks Gestational Age
NCT01159262
A Study Comparing the Effects of Epoetin Hospira and Epogen/Epoetin Alfa (Amgen) When Administered IV in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment
NCT01170078
Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects
NCT00875550
A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects
NCT01812538
Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects
NCT00652028
Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery
NCT00709436
Bioequivalency Study Comparing Hospira's Generic Iron Sucrose Injection to Venofer
NCT00719459
Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients
NCT00492388
A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Hip Fracture Repair Surgery
NCT00460473
A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation During Monitored Anesthesia Care (MAC)
NCT00398827
A Safety and Efficacy Study of Dexmedetomidine in Patients Requiring Sedation for Elective Awake Fiberoptic Intubation
NCT00383890
A Safety and Efficacy Study of Dexmedetomidine in ICU Patients Requiring Continuous Sedation
NCT00216190
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
| Phase 3 | 6 |
| Phase 4 | 2 |
Therapeutic Areas
What the Pipeline for Hospira, now a wholly owned subsidiary of Pfizer Shows
According to the ClinicalTrials.gov registry, Hospira, now a wholly owned subsidiary of Pfizer is linked to 15 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting, about 0% of the sponsor's indexed portfolio, and 13 are already marked complete, representing roughly 87% of the total.
The phase mix for Hospira, now a wholly owned subsidiary of Pfizer reports 8 late-stage studies (Phase 3 and Phase 4 combined) and 7 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Hospira, now a wholly owned subsidiary of Pfizer is Ventricular Repolarization with 1 linked trial, and 2 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.